Walleye Capital
BLTE

Walleye Capital’s Belite Bio BLTE Stock Holding History

Walleye Capital’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.88M Buy
+31,721
New +$4.86M 0.02% 841

Other funds holding BLTE

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
HNWAG
High Net Worth Advisory Group Naples, Florida $471M AUM 22.07% 1-Year Est. Return
DACS
Dymon Asia Capital (Singapore) Singapore $2.39B AUM 150.5% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
EFMH
E Fund Management (HK) Central, Hong Kong $302M AUM 64.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
WPA
West Paces Advisors Atlanta, Georgia $596M AUM 22.29% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Walleye Capital's BLTE Position: Q2 2026 in Review

Walleye Capital opened a new position in Belite Bio (BLTE) in Q2 2026: 31,721 shares worth $4.88M. The stake represents 0.02% of the portfolio and ranks #841 among its holdings.

12 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Walleye Capital held 31,721 shares of Belite Bio worth $4.88M as of Q2 2026.
  • Belite Bio was a new Walleye Capital position in Q2 2026.
  • Belite Bio made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #841 holding.
  • 12 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.